Chief Commercial Officer and Chief Technology Officer

BIGFOOT BIOMEDICAL NAMES JYOTI PALANIAPPAN AS CHIEF COMMERCIAL OFFICER AND IAN HANSON AS CHIEF TECHNOLOGY OFFICER

Digital Drug Delivery Company Developing Insulin Delivery Solutions Adds Commercialization Muscle to C-Suite

Milpitas, CA, October 16, 2018 – Bigfoot Biomedical, Inc., a diabetes solutions and digital health company using artificial intelligence to optimize the dosing and delivery of insulin for people with insulin-requiring diabetes, today announced the appointment of Ian Hanson and Jyoti Palaniappan to its executive leadership team, in the roles of Chief Technology Officer and Chief Commercial Officer, respectively.

Bigfoot is developing a portfolio of insulin delivery solutions intended to alleviate many challenges for people with Type 1 and Type 2 insulin-requiring diabetes and their healthcare providers. The company is developing and trialing a comprehensive service, leveraging smartphone connectivity and delivered as a subscription for optimized and automated insulin delivery, that helps people with insulin-requiring diabetes deliver insulin safely and effectively, supports healthcare providers in improving health outcomes efficiently, and enables payers to improve population health while reducing the cost of care.

Ian Hanson comes most recently from Unilife, where he served as Senior Vice President and Chief Operating Officer and led the development of their industry-leading wearable injector platform and advanced drug delivery systems. Prior to Unilife, Hanson held senior leadership roles with Medtronic Diabetes where he created their Advanced and Systems Engineering Department and was responsible for development and commercialization of insulin delivery devices and diabetes management systems for over a decade. As Bigfoot’s Chief Technology Officer, Hanson will lead an R&D team of over 40 engineers in software, hardware, firmware, and design assurance as they work to finalize development and commercialization of the Bigfoot ecosystem.

Jyoti Palaniappan, Chief Commercial Officer, spent the last eleven years at Abbott serving in executive commercial roles. He first held sales and marketing leadership roles in the U.S. commercial operations where he had responsibility for market access, healthcare professional, and pharmacy & DME channels. Most recently, Jyoti served in a strategic leadership role in the Global commercial operations where he supported Abbott’s launch for FreeStyle Libre. Prior to Abbott, Palaniappan led global and US commercial organizations for Thermo Fisher Scientific in the field of genomics and provided strategic consulting services at McKinsey & Company in the areas of sales & marketing, product launch, and corporate strategy. As Chief Commercial Officer, Palaniappan brings a wealth of experience in product management, product launch strategy, marketing, sales, customer care, business development, and reimbursement, in both US and global contexts.

“Ian and Jyoti bring with them an impressive depth of experience in drug delivery systems, device development, and health technology commercialization,” said Jeffrey Brewer, Bigfoot Biomedical co-founder, and CEO. “I'm thrilled by what Jyoti and Ian will add to the Bigfoot team and eager to see them apply their tangible passion and deep expertise to our vision for an easier, safer, and better life for people with diabetes.”

“I’m very excited about the impact Bigfoot is going to have in this space,” said Ian Hanson. “This team has a drive and energy that sets it apart, with the background and expertise to realize a category-defining vision.”

“It is amazing to see over 100,000 people following Bigfoot on Facebook already, patiently waiting for Bigfoot products to launch,” said Jyoti Palaniappan. “I am truly humbled and energized to join this passionate team who are working hard to get Bigfoot’s patient-centered designed, innovative products into the hands of people with insulin-requiring diabetes as quickly as possible.”

Bigfoot Biomedical anticipates a commercial launch of its first two systems, Bigfoot Loop and Bigfoot Inject, in 2020, pending completion of a pivotal clinical trial and subsequent regulatory approvals.

About Bigfoot Biomedical, Inc.
Bigfoot Biomedical was founded by a team of people with a personal connection to type 1 diabetes. With its Loop and Inject systems, the company seeks to reduce the burden of living with insulin-requiring diabetes and to maximize the leverage of health care providers through data, connectivity, automation, and artificial intelligence. Learn more at bigfootbiomedical.com. Follow us on Twitter @BigfootBiomed and Facebook.

Media Contacts:
Melissa Lee
mlee@bigfootbiomedical.com

Download full press release